Study	Reason for exclusion
Anon 2001f	Commentary on GAL‐INT6
Anon 2001g	Commentary on GAL‐INT6
Bickel 1991	Pharmacokinetics study
Bores 1994	Pharmacokinetics study
Brashear 2003	GAL‐INT‐6
Brodaty 1996	Review article
Bullock 2001	Conference abstract‐ preliminary data from GAL‐INT‐6
Bullock 2004	Open label extension to GAL‐INT‐6
Burke 2002	Conference abstract describing NPI from GAL‐USA‐10 & GAL‐INT‐6
Caro 2002	Post hoc, subgroup, or selected combined exploratory analyses
Clegg 2001	HTA report covering all three cholinesterase inhibitors
Clegg 2002	Summary of HTA report (Clegg 2001)
Corey 2003	Review only
Coyle 2001	Review only
Cummings 2003	Review only
Cummings 2004	post hoc, subgroup, or selected combined exploratory analyses
Dal Bianco 1991	Not placebo‐controlled
Dengiz 2004	Review only
Doran 2003	Randomised different washout periods before switching from Donepezil to Galantamine; no results on register, not on Medline.
Erkinjuntti 2002a	Reply to Van Gool re GAL‐INT‐6
Erkinjuntti 2002b	Letter summarising GAL‐INT‐6
Erkinjuntti 2003	Open‐labelled 6 month extension to GAL‐INT‐6
Fulton 1996	Review article
GAL‐COG‐3002 2005	Pooled MCI mortality data from different trials‐ referred to in Discussion/ Other references
GAL‐MCI‐301 2004	Open‐label extension to MCI studies‐ stopped
Galasko 2004	post hoc, subgroup, or selected combined exploratory analyses
Gold 2004a	Superceded by Brodaty 05
Gold 2004b	Conference abstract only: GAL MCI trial baseline data
Hager 2004	Conference abstract only: open‐label uncontrolled study
Haworth 2003b	Rater‐blinded randomised trial of donepezil vs. galantamine. Likely to have been reported as Wilcock03 in Drugs Aging.
Janssen 2005	Prescription information only.
Jones 2004	GAL vs. Donepezil‐ RCT but open‐labelled
Kertesz 2002	Comment on GAL‐INT‐6
Kewitz 1994	Not double‐blind
Kewitz 1997	Pharmacokinetics study
Kurz 1998	GAL‐INT‐6
Kurz 2002	Non‐cognitive outcome of GAL‐INT‐6
Kurz 2003	Open‐label extension to GAL‐INT‐6
Kurz 2004	Conference abstract only, two Donepezil to GAL switching studies: randomizing washout period and galantamine dose
Lilienfeld 2001	Conference abstract on additional outcome (carer time requirement) from GAL‐INT‐1
Lyketsos 2002	Conference abstract reporting serial ADAS‐cog up to 18.5 months from extension studies (from which 2 RCTs: unclear)
Lyketsos 2004	Open‐label extension to Raskind and Tariot
MacGowan 1998	Not placebo‐controlled
Marder 2002	Comment on GAL‐INT‐6
Markowitz 2003	post hoc, subgroup, or selected combined exploratory analyses
Mintzer 2000	Preliminary conference abstract for Mintzer 2003 (see 'other references: additional references')
Mintzer 2001	Conference abstract comparing uncontrolled open label data at twelve months against historical controls
Moretti 2002	Comment on GAL‐INT‐6
Morris 2002	Conference abstract: 18.5 month open label extension study of GAAL‐USA‐10 and another unspecified trial
Mucke 1997	Review article. Preclinical studies
Nordberg 1998	Review article. Pharmacokinetics study
Novak 2004	Conference abstract only: effect of MCI clinical subtype on GAL efficacy‐ outcome not stated in abstract
Nye 2004	Conference abstract only: effect of ApoE genotype on GAL efficacy‐ outcome not stated in abstract
Orgogozo 2004	Superceded by subsequent paper in Current Medical Research & Opinion, which will be included under 'Other References'
Paskov 1974	Subjects did not have a diagnosis of dementia. Study was examining sexual function
Patterson 2002	Conference abstract: six month open label study (N=36)
Ping 2000	Randomised against Huperzine
Rabheru 2004	Conference abstract only, pooling behavioral outcome from 3 RCTs (details not stated)
Rainer 1993	Abstract with insufficient data
Rainer 1994	Single blind trial, not placebo controlled
Rainer 1997a	Review article
Rainer 1997b	Review article
Rainer 2001	Cross sectional study assessing cognition post drug cessation; only 5 patients on galantamine
Raskind 2000	Conference abstract reporting GAL‐USA‐1
Riemann 1994a	Subjects did not have a diagnosis of dementia. Outcome measure was sleep pattern.
Riemann 1994b	Review article on sleep and cholinergic function.
Sano 2003b	post hoc, subgroup, or selected combined exploratory analyses
Scheltens 2004	Conference abstract only: atrophy as outcome in MCI trial‐ methodology only: outcome not stated in abstract
Schwalen 2004a	Conference abstract only: pooled efficacy data for patients with baseline ADAS‐cog>30 pooled from 6 studies (details not in abstract), examining continuous vs. interrupted vs. delayed treatment.
Schwalen 2004b	Conference abstract only: post‐hoc analysis of pooled data for patients with baseline MMSE <18 randomised to 24mg or 16mg/d
Scott 2000	Review only
Small 2003	Posthoc analysis of GAL‐INT‐6 plus open‐label extension
Snorrason 1996	Subjects did not have a diagnosis of dementia. Not a clinical trial
Steiger‐Baechler 200	Case description of cognition in 7 patients post cholinesterase inhibitor cessation‐ none on galantamine
Tariot 2000	Preliminary conference abstract for GAL‐USA‐10 Tariot
Thomsen 1990	Not a clinical trial
Thomsen 1990a	Not a randomized clinical trial
Thomsen 1990b	Not a clinical trial
Truyen 2000a	summary presentation of earlier galantamine findings
Truyen 2000b	summary presentation of earlier galantamine findings
Truyen 2001	specific data not included in abstract
van Gool 2002	Comment on GAL‐INT‐6
Vellas 2004	Conference abstract only: Pooled data on changes in DAD score/ADL from 6 RCTs
Wasielewski 1997	Review article
Wilcock 1993	Not placebo‐controlled
Wilcock 2000i	Conference abstract on additional outcome (carer time requirement) from RCTs, referenced to Blesa 2000.
Wilcock 2000j	Conference abstract comparing uncontrolled open label data at twelve months against historical controls.
Wilkinson 2000	Conference abstract reporting GAL‐INT‐2
Zarotsky 2003	Review only